中文产业新闻评分66Chinese source
阿斯利康SAFFRON III期试验获该患者群体首个PFS与OS双终点显著获益
阿斯利康喜提全球首个OS，痛失双抗一线梦
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
阿斯利康喜提全球首个OS，痛失双抗一线梦
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.